Ausgabe 5/2024
Inhalt (11 Artikel)
Inhibition of proteinase-activated receptor 2 (PAR2) decreased the malignant progression of lung cancer cells and increased the sensitivity to chemotherapy
Hongjie Huo, Yu Feng, Qiong Tang
Ruthenium–dihydroartemisinin complex: a promising new compound for colon cancer prevention via G1 cell cycle arrest, apoptotic induction, and adaptive immune regulation
Chong-Zhi Wang, Chunping Wan, Cang-Hai Li, Guo-Gang Liang, Yun Luo, Chun-Feng Zhang, Qi-Hui Zhang, Qinge Ma, Angela H. Wang, Mallory Lager, Ting-Liang Jiang, Lifei Hou, Chun-Su Yuan
Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells
Thamir M. Mahgoub, Emmet J. Jordan, Amira F. Mahdi, Veronika Oettl, Stefanie Huefner, Norma O’Donovan, John Crown, Denis M. Collins
Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants
Romain Sechaud, Helen Gu, Gholamreza Rahmanzadeh, Amanda Taylor, Ovidiu Chiparus, Gopal Krishna Sharma, Astrid Breitschaft, Hans D. Menssen
Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells
Alexandr N. Chernov, Alexandr V. Kim, Sofia S. Skliar, Evgeniy V. Fedorov, Anna N. Tsapieva, Tatiana A. Filatenkova, Aleksei L. Chutko, Marina V. Matsko, Elvira. S. Galimova, Olga V. Shamova
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study
Bin Fan, Ghassan K. Abou-Alfa, Andrew X. Zhu, Shuchi S. Pandya, Hongxia Jia, Feng Yin, Camelia Gliser, Zhaowei Hua, Mohammad Hossain, Hua Yang
The landscape of very important pharmacogenes variants and potential clinical relevance in the Chinese Jingpo population: a comparative study with worldwide populations
Xiaoya Ma, Yujie Li, Xufeng Zang, Jinping Guo, Wenqian Zhou, Junhui Han, Jing Liang, Panpan Wan, Hua Yang, Tianbo Jin
Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors
Kadriye Bir Yücel, Uguray Aydos, Osman Sütcüoglu, Atiye Cenay Karabörk Kılıç, Nuriye Özdemir, Ahmet Özet, Ozan Yazıcı
Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report
M. Berge, J. S. Giraud, S. De Percin, A. Puszkiel, A. Thomas-Schoemann, B. Blanchet
Retraction Note: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment
Mototsugu Oya, Shuichi Kaneko, Tsuneo Imai, Toshiaki Tsujino, Toshiyuki Sunaya, Yutaka Okayama